U.S.-listed shares of Novo Nordisk (NVO) fell sharply for a second straight day Wednesday, this time after Bank of America ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

But it might not be long before a new option becomes available for anyone on a weight loss journey, thanks to a breakthrough ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Danish leader will face a challenging landscape among competitors ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

More than 60 billion euros (£52 billion) has been wiped off the stock market value of Ozempic and Wegovy weight loss drug firm Novo Nordisk after it warned over sales and profits ...

In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...